NEW YORK (GenomeWeb News) – RNAi services firm Cenix BioScience said today that it has extended an existing collaboration with CellCentric to validate epigenetic oncology drug candidates.
 
The new project follows a pilot study that the companies began in March under which Cenix used its RNAi-based phenotypic characterization platform to study several of CellCentric’s drug target candidates in a diverse panel of human cell lines.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.